

1 **Comparative analysis of the multiple absorbed bioactive**
2 **components in rat serum after oral administration of Xiexin**
3 **Tang by HPLC-DAD coupled with HPLC-Q-TOF/MS**

4 Xiaoyu Wang¹, Shujiao Li², Yuqing Wang^{2,*}, Guo Zhuang², Dong Shui², Rui Hu^{1,*}

5
6 ¹*Department of Pharmacology, Shaanxi University of Chinese Medicine, Shaanxi Xiayang*
7 *712046, China; ²Center of Scientific Research, Nanyang Medical College, Nanyang 473061,*
8 *China*

9
10 * Corresponding author. Tel./Fax: +86 377 63526575

11 E-mail address: wyyq2013@163.com; hu_xiaorui@163.com

12

1 **Abstract: Background:** Xiexin Tang (XXT) is a classic traditional Chinese medicine (TCM)
2 formula administered in clinics for more than 1800 years. Recently, many studies have
3 investigated the pharmacological effects and chemical composition of XXT. However, systematic
4 studies on the material basis of its efficacy are lacking. In present study, the serum
5 pharmacochemistry technique and high-performance liquid chromatography diode-array detection
6 (HPLC-DAD) coupled with quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF/MS) was
7 performed to screening and analysis of the multiple absorbed bioactive components and
8 metabolites of orally dosed XXT in rat serum.

9 **Methods:** Bio-samples and herbal extracts were analyzed and detected by HPLC-DAD coupled
10 with HPLC-Q-TOF/MS. Upon comparison of the chromatograms of the single-constituent
11 decoctions with that of the XXT formulation, the peak number and intensity of the formulated
12 decoction showed some variation from those of the single-constituent decoctions.

13 **Results:** Twenty-one serum-adsorbed constituents were identified after intragastric administration
14 of herbal extracts, of which 8 originated from Rhei Radix et Rhizoma (RRR), 5 from Coptidis
15 Rhizoma (CR), and 8 from Scutellariae Radix (SR). The results show that the main adsorbed
16 constituents in the serum were anthraquinones, anthrones, chromones, and butyrophenones for
17 RRR, alkaloids for CR, and flavonoids for SR.

18 **Conclusion:** The results demonstrate that an effective and reliable analytical method is set up for
19 screening the bioactive components of Chinese herbal medicine, which provided a meaningful
20 basis for further pharmacology and active mechanism research of XXT.

21

- 1 **Keywords:** Xiexin Tang, Serum pharmacochemistry, Bioactive components, HPLC-DAD,
- 2 HPLC-Q-TOF/MS
- 3

1 1 INTRODUCTION

2 In recent years, the natural medicine and traditional Chinese medicine (TCM) have been
3 widely researched and used in the world. Finding the active ingredients or leading compounds in
4 traditional Chinese medicine is one of the important means of developing new drugs, such as
5 resveratrol [1], tanshinone [2], ginseng saponin [3] and so on. The research of herbal extracts is
6 also increasing gradually, such as Ginkgo biloba extract. However, these researches mostly
7 focused on the study of natural medicine or one or some components of traditional Chinese
8 medicine, which was equivalent to chemicals in research strategy rather than the practical
9 application of traditional Chinese medicine with thousands of years history in China. The
10 compatibility of traditional Chinese medicine prescription is one of the important characteristics of
11 TCM in conventional sense, while the complexity of TCM compound ingredients has been
12 become a bottleneck restricting the research of Chinese medicine. Serum pharmacochemistry of
13 TCM, a combination of traditional pharmacochemical methods and modern analytical techniques,
14 such as chromatography and mass spectrometry, has been used to identify the effective
15 constituents of TCMs that migrate into the serum after absorption. This enables investigations of
16 their efficacy and the identification of the active ingredients of TCM [3, 4]. Using this approach,
17 Wang *et al* studied the bio-pharmacodynamics of Yin-Chen-Hao decoction and the active
18 ingredients of Liu-Wei-Di-Huang pills, and achieved good results [5-8]. This method has been
19 widely recognized and applied as a major method for studying the material basis of Chinese
20 medicine.

21 Xiexin Tang (XXT), first recorded in the *Essential Prescriptions of the Golden Cabinet*
22 (150-220 A.D., Han Dynasty) and employed in clinical settings for 1800 years, is composed of
23 Rhei Radix et Rhizoma (RRR), Coptidis Rhizoma (CR) and Scutellariae Radix (SR) [9]. Modern
24 pharmacological studies reveal that XXT has various properties including anti-inflammatory
25 [10,11], antimicrobial [12], gastroprotective [13-15], and antihypotensive effects [16]. This
26 prescription is particularly useful for treating patients with digestive tract disease, cardiovascular
27 disease, etc. [17]. RRR, the radix and rhizoma of *Rheum palmatum* L., *Rheum tanguticum* Maxim.
28 ex Balf. and *Rheum officinale* Baill, a commonly used traditional Chinese medicine, is a sovereign

1 herb, which purges fire and toxins, clears the viscera and guides the descending of fire. The
2 researches have shown that RRR has the regulating effects on gastrointestinal functions,
3 anti-inflammatory, anti-pathogen, cardiovascular protective, antitumor, hepatoprotective,
4 choleric and anti-ageing effects as well as other pharmacological actions. CR, the rhizoma of
5 *Coptis chinensis* Franch., *Coptis deltoidea* C. Y. Cheng et Hsiao and *Coptis teeta* Wall. CR has a
6 long history of usage for clearing heat, eliminating dampness, purging fire and detoxification
7 inTCM. CR, also called goldthread, was frequently used for the treatment of bacillary dysentery,
8 typhoid, tuberculosis, epidemic cerebrospinal meningitis, empyrosis, pertussis, and other diseases.
9 SR, the radix of *Scutellaria baicalensis* Georgi, has been used for thousands of years in traditional
10 Chinese medicines, which was firstly cited in Shennong Bencao Jing (200-300 a.d., Han Dynasty),
11 a classical masterpiece of TCM [18]. SR has been long used for antibacterial, antiviral,
12 anti-inflammatory, antioxidation, protecting liver and protect cardiovascular system, etc. Although
13 many studies have investigated the pharmacological effects and chemical composition of XXT,
14 but, systematic studies on the material basis of its efficacy are lacking.

15 It is believed that the analysis of serum pharmacology of traditional Chinese medicine
16 will play an important role as an effective tool in terms of high-throughput elucidation of
17 metabolic phenotypes of XXT. Thus, in this paper, a serum pharmacology of traditional
18 Chinese medicine approach based on a combination of high-performance liquid chromatography
19 diode array detection (HPLC-DAD) coupled with quadrupole time-of-flight mass spectrometry
20 (HPLC-Q-TOF/MS) was adopted to screen and analyze the multiple absorbed bioactive
21 components and metabolites of XXT in *vivo*.

22
23

1 **2 MATERIAL AND METHODS**

2 **2.1 Reagents and Materials**

3 Reference standards of aloecemodin, rhein, coptisine, epiberberine, jatrorrhizine, palmatine,
4 berberine, wogonin, wogonoside, baicalin and baicalein were purchased from Shanghai yuanye
5 Bio-Technology Co., Ltd (Shanghai, China); emodin and chrysophanol were purchased from
6 Chengdu Institute of Biology, Chinese Academy of Sciences (Chengdu, China). Ultra-pure water
7 was obtained by using a Milli-Q reference super purification system (Merck Millipore, Germany).
8 Distilled water was used for the extraction and preparation of samples. All the solvents (HPLC
9 grade) were acquired from Fisher Scientific (Massachusetts, America) and other chemicals
10 (analytical grade) were obtained from Tianjin Fuchen Chemical Research Factory (Tianjin, China)
11 unless otherwise stated.

12 **2.2 Sample Preparation**

13 Rhei Radix et Rhizoma, Coptidis Rhizoma and Scutellariae Radix were purchased from
14 Fengyuan Tongling Crude Drug Company (Bozhou, China) and were identified by Professor
15 Yu-qing Wang (Nanyang Medical College, Nanyang, China). A total of 400 g mixed herbal slice
16 of RRR, CR, and SR (2:1:1, w/w/w) were extracted once with boiling water (1:10) for 90 min and
17 filtered through gauze. The residue was refluxed with boiling water (1:8) for 60 min and again
18 filtered through gauze. The two filtrates were merged and evaporated with rotary evaporator under
19 vacuum, thus XXT extract was obtained. Then XXT extract was further vacuum-dried. The herbs
20 RRR (200 g), CR (100 g), and SR (100 g) were individually extracted through the same procedure,
21 and then the dried extracts of RRR, CR, and SR could also be obtained. The yield of dry extracts
22 from XXT, RRR, CR, and SR were 31%, 43%, 26%, and 38% (3.2 g, 2.32 g, 3.85 g and 2.63 g
23 crude herbs per 1 g extract) respectively. Each dry extract was weighed and placed in a 10 mL
24 volumetric flask. Methanol was added to the extract and the resulting solution was left in an
25 ultrasonic bath for 30 min. After this, the final volume was adjusted to 10 mL with methanol for
26 final crude drug concentrations of 0.32 g/mL, 0.16 g/mL, 0.08 g/mL and 0.08 g/mL of XXT, RRR,
27 CR, and SR, respectively.

28 **2.3 Preparation of Standard Solutions**

1 Stock solutions were separately prepared separately by dissolving the accurately weighed
2 eight chemical standards with methanol. A mixed stock solution was obtained by mixing coptisine,
3 epiberberine, jatrorrhizine, palmatine and berberine, and giving a final concentration of 102.0,
4 30.0, 44.6, 79.8 and 371.5 $\mu\text{g}/\text{mL}$, respectively. Then another mixed stock solution was obtained
5 by mixing aloecemodin, rhein, wogonin, wogonoside, baicalin, baicalein, emodin and chrysophanol,
6 and giving a final concentration of 27.5, 8.8, 164.0, 55.3, 718.1, 24.0, 6.0 and 10.0 $\mu\text{g}/\text{mL}$,
7 respectively. All solutions prepared from the plant materials and standard compounds were stored
8 at 4°C for later use.

9 **2.4 In vivo Experiments Protocol**

10 Male Sprague-Dawley rats (200 ± 20 g) were provided by Hunan SJA Laboratory Animal
11 Co., Ltd (Changsha, China). The rats were allowed to acclimatize for seven days in a
12 well-ventilated room at a temperature of $24 \pm 2^\circ\text{C}$ and a relative humidity of $50 \pm 5\%$, with a 12 h
13 light/dark cycle. Food and tap water were provided ad libitum. The protocol was approved by the
14 Animal Experimental Ethical Committee of Nanyang Medical College. All efforts were made to
15 ameliorate suffering of animals.

16 After one week of acclimatization, the rats were randomly divided into 5 groups with 6 rats
17 in each: the control, XXT, RRR, CR, and SR groups. The rats in XXT, RRR, CR, and SR groups
18 were intragastrically given XXT, RRR, CR, and SR extracts at a dose of 18 g/kg, 9 g/kg, 4.5 g/kg,
19 and 4.5 g/kg (18 g, 9 g, 4.5 g and 4.5 g crude herbs per 1 kg rat body weight) dissolved and
20 dispersed homogeneously in ultrapure water, respectively. The animal dose of XXT, RRR, CR,
21 and SR extracts was extrapolated from the human daily dose, using the body surface area
22 normalization method. The formula for dose translation was as follows: human dose of crude
23 herbs in clinic $\times 0.018/200 \times 1000 \times$ the multiple of clinical equivalency dose (Li *et al*, 2012). The
24 dose of XXT, RRR, CR, and SR extracts was equivalent to ten times of the adult daily dose XXT,
25 RRR, CR, and SR (from XXT (20 g) in which RRR, CR, and SR were 10 g, 5 g and 5 g,
26 respectively) crude herbs based on the TCM prescription. Model groups were intragastrically
27 given the same volume of saline solution. All animals were administered by oral gavage two times
28 each day for continuous 6 times. Blood samples (0.5 mL) of rats were collected by posterior

1 orbital venous plexus after the last dose into 1.5 mL Eppendorf centrifuge tubes. After keeping for
2 2 h in still position, the blood samples were centrifugated at 3000 r for 10 min. Then, the serum
3 samples were separated and stored at $-80\text{ }^{\circ}\text{C}$ until analysis.

4 **2.5 Samples Preparation**

5 Serum samples were thawed at room temperature before preparation. Acetonitrile (600 μL)
6 was added into each serum sample (200 μL) to precipitate protein. Afterwards, the mixture was
7 vortexed for 30 s and centrifuged at 13,000 rpm for 10 min. Then, 450 μL supernatants of the
8 serum samples were transferred into new tubes and evaporated to dryness under vacuum,
9 respectively. The residues of serum samples were dissolved in 200 μL of 70% acetonitrile solution,
10 and the mixtures were vortexed for 1 min, and centrifuged at 13,000 rpm for 10 min at 4°C .
11 Finally, a 5 μL aliquot of supernatant was injected for HPLC-MS analysis.

12 In addition, the serum samples were randomly selected from each group and mixed together
13 as the quality control (QC) samples, respectively. This pooled sample was used to provide a
14 representative “mean” sample containing all analytes that was encountered during the analysis,
15 and it was used to validate stability of HPLC-Q-TOF/MS system. The QC samples were injected
16 five times at the beginning of the run in order to condition or equilibrate the system and then every
17 ten samples to further monitor the stability of the analysis. The acquired QC data were used to
18 investigate the analytical variability in the whole run. This was necessary in order to evaluate
19 whether the analytical system had changed (and to what extent) over the time course of the
20 analysis, and essential for evaluating the variation in the analytical results and therefore the
21 reliability of the metabolite profiling data [19-22].

22 **2.6 HPLC-DAD and HPLC-Q-TOF/MS Conditions**

23 The HPLC analysis was performed on an Agilent 1260 HPLC system (Agilent, USA).
24 Samples were separated on an Agilent Poroshell 120 EC- C_{18} column ($3 \times 150\text{ mm}$, $2.7\text{ }\mu\text{m}$)
25 protected by a 5 mm guard column using gradient elution. The mobile phase consisted of two
26 solvents: solvent A was a mixture of 0.02 mol/L ammonium acetate in water-acetic acid ($\text{pH} = 3.5$)
27 and solvent B was 100% acetonitrile. Gradient elution was performed as follows: 0–4 min,
28 2%–24.5% B; 4–14 min, 24.5%–26.3% B; 14–17 min, 26.3%–30% B; 17–20 min, 30%–90% B;

1 20-26 min, 90% B. An aliquot of 5 μ L of sample solution was injected into the Poroshell 120
2 EC-C₁₈ column. The flow rate was 0.5 mL/min, and column was maintained at 40°C. UV-Vis
3 chromatograms were recorded at 260 nm by diode-array detection (DAD). MS was performed on
4 a G6530 Q-TOF/MS (Agilent, USA). The instrument was operated by using electrospray
5 ionization (ESI) source in positive and negative mode. The ionization source conditions were as
6 follows: gas temperature of 320°C, drying gas flow rate of 8 L/min, nebulizer pressure of 40 psig,
7 sheath gas temperature of 300°C, sheath gas flow rate of 12 L/min, and capillary voltage of 3.5 kV.
8 An acquisition time of 500 ms was used throughout with an acquisition rate of 2 spectra. The
9 skimmer voltage was set at 65 v and Oct/RF V_{pp} was 750 v. Recalibration reference mass
10 parameters were as follows: detection window of 50 ppm and minimum height of 1000 counts.
11 The MS data were collected from *m/z* 100 to 1700 Da in positive and negative ion modes, and
12 stored in centroid mode.

13 **3 RESULTS**

14 **3.1 The Establishment of Methodology of Serum Sample**

15 Representative base peak intensity chromatograms of the serum samples are shown in Fig. 1.
16 The extracted ion chromatographic peaks of 21 ions (547.1453, 547.1451, 409.0772, 461.1089,
17 445.0775, 459.0930, 338.1389, 336.1227, 320.0912, 459.0928, 352.1546, 336.1228, 431.0975,
18 227.0714, 283.0248, 269.0451, 269.0457, 283.0609, 283.0614, 269.0452 and 253.0506 in serum
19 sample) were selected for method validation [19, 20, 22]. The repeatability of method was
20 evaluated by using five replicates of QC sample. The relative standard deviations (RSD%) of peak
21 areas, retention times and *m/z* were 1.11-5.95%, 0-0.28% and 0.00014-0.0026%, respectively. The
22 post-preparation stability of samples was tested by analyzing QC sample kept in auto sampler at
23 4°C for 0, 4, 8, 12 and 24 h. The relative errors of peak areas were less than 6.87%, which
24 demonstrated that the method had excellent repeatability and stability.

25 **3.2 Identification of Absorbed Bioactive Components**

26 Through the analysis of the serum samples at multiple blood collection time points, the serum
27 samples of XXT were provided with Rhei Radix et Rhizoma, Coptidis Rhizoma and Scutellariae

1 Radix for 1 h, with the highest quality fraction. The quantity and quality fraction of the serum
2 samples decreased significantly after ig 2 h, so the serum samples were analyzed with 1 h.

3 Using HPLC, XXT, single-constituent decoctions, drug-containing serum, and blank serum
4 were analyzed and compared to identify the source of the absorbed constituents. A total of 21
5 transitional constituents were identified in the rat serum samples after intragastric administration
6 of XXT (Fig. 1), of which peaks 3, 4, 13–15, 17, 20 and 21 originated from DH (Fig. 2), peaks
7 7–9, 11, and 12 from HL (Fig. 3), and peaks 1, 2, 5, 6, 10, 16, 18, and 19 from HQ (Fig. 4).

8 The chromatograms of the DH decoction and its corresponding serum samples are shown in
9 Fig. 2. After comparing the retention time, UV absorption spectra, and mass spectral data of each
10 compound with that of the control, we preliminarily identified peak 3 as
11 2-methyl-5-carboxymethyl-7-hydroxychromoglucuronide, peak 4 as 2-*O*-cinnamoyl-glucogallin,
12 peak 13 as emodin glucoside, peak 14 as resveratrol, peak 15 as rhein, peak 17 as aloe aloemodin,
13 peak 20 as emodin, and peak 21 as chrysophanol (Table 1).

14 The chromatograms of the HL decoction and its corresponding serum samples are shown in
15 Fig. 3. After comparing the retention time, UV absorption spectra, and mass spectral data of each
16 compound with the that of the control, we preliminarily identified peak 7 as jatrorrhizine, peak 8
17 as epiberberine, peak 9 as coptisine, peak 11 as palmatine, and peak 12 as berberine (Table 1).

18 The chromatograms of the HQ decoction and its corresponding serum samples are shown in
19 Fig. 4. After comparing retention time, UV absorption spectra and mass spectral data of each
20 compound with that of the control, we preliminarily identified peak 1 as
21 6-*C*-arabinosyl-8-*C*-glucosyl-chysin, peak 2 as 6-*C*-glucosyl-8-*C*-arabinosyl-chrysin, peak 5 as
22 baicalin, peak 6 as oroxylin glucoside, peak 10 as wogonoside, peak 16 as baicalein, peak 18 as
23 wogonin, and peak 19 as oroxylin (Table 1).

24 3.3 Identification of Absorbed Bioactive Components from DH

25 3.3.1 Anthraquinones

26 The retention time of compound 13 was 15.022 min and its quasi-molecular ion peak was m/z
27 431.0975 $[M-H]^-$. With tandem MS, the parent ion was cleaved into fragment m/z 269.0448 after
28 losing a glucose molecule. Fragment m/z 269.0448 was then further cleaved into m/z 241.0502 and

1 m/z 225.0551, which followed the same cleavage pathway as that of emodin. Therefore, it was
2 concluded that compound **13** was emodin glucoside [23]. The retention time of compound **15** was
3 18.713 min and its quasi-molecular ion peak was m/z 283.0248 $[M-H]^-$. It was then fragmented
4 into m/z 257.0452 $[M-H-COH_2]^-$ after losing CO, and each of the two adjacent carbons bonded
5 with a hydrogen. Fragment m/z 239.0344 $[M-H-CO_2]^-$ was the major product after the molecular
6 ion lost one CO₂. After comparing with the control samples, compound **15** was identified as rhein
7 [24]. The cracking pathway is shown in Fig. 5. The retention time of compound **17** was 21.824
8 min. The quasi-molecular ion peak, m/z 269.0457 $[M-H]^-$, lost one uncharged CO molecule and
9 an oxygen atom, forming m/z 225.0555 $[M-H-CO-O]^-$. Fragment m/z 223.0393
10 $[M-H-CO-H_2O]^-$, was the major product of the molecular ion and formed by losing H₂O and CO.
11 Fragment m/z 240.0425 $[M-H-COH]^-$, was inferred to be the product of the molecular ion after
12 losing CO and one hydrogen atom. Additional cross-referencing with the control samples revealed
13 that compound **17** was aloemodin [25]. The retention time of compound **20** was 22.752 min.
14 After losing an uncharged CO molecule, the quasi-molecular ion peak, m/z 269.0452 $[M-H]^-$,
15 became fragment m/z 241.0505 $[M-H-CO]^-$. The m/z 225.0554 was the product of m/z 241.0505
16 losing one oxygen atom. After comparing with control samples, compound **20** was identified as
17 emodin [26]. The retention time of compound **21** was 23.882 min. Its quasi-molecular ion peak
18 was m/z 253.0506 $[M-H]^-$, which fragmented to form m/z 239.0342 $[M-H-CH_2]^-$ after losing
19 CH₂, and the fragment m/z 225.0551 $[M-H-CO]^-$ was formed after the quasi-molecular ion lost
20 an uncharged CO. After cross-referencing with the control samples, compound **21** was identified
21 as chrysophanol [27]. The cracking pathway is shown in Fig. 6.

22 **3.3.2 Stilbene**

23 The retention time of compound **14** was 15.951 min and its quasi-molecular ion peak was m/z
24 227.0714 $[M-H]^-$, which fragmented into m/z 185.0606 after losing C₂H₂O, and m/z 143.0496
25 after losing C₄H₄O₂. Fragment m/z 143.0496 was then further cleaved into m/z 117.0342 after
26 losing C₂H₃⁻. After cross-referencing with the literature, compound **14** was identified as
27 resveratrol [28]. The cracking pathway is shown in Fig. 7.

28 **3.3.3 Chromone**

1 Under the negative ion mode, the full scan MS revealed that the quasi-molecular ion was m/z
2 409.0772 $[M-H]^-$, with a retention time of 8.212 min for compound **3**. Additional full-scan
3 tandem MS showed main fragment ions of m/z 365.0869, 233.0452 and 189.0554, which were
4 identified as fragments of the quasi-molecular ion without CO_2 , $C_6H_8O_6$ and $CO_2+C_6H_8O_6$,
5 respectively. Fragment ions of m/z 175.0241, 149.0452 and 131.0346, were identified as
6 characteristic ion peaks of glucuronic acid. After cross-referencing with the literature, compound **3**
7 was preliminarily identified as 2-methyl-5-carboxymethyl-7-hydroxyl chromoglucuronide [29].
8 The cracking pathway is shown in Fig. 8.

9 **3.3.4 Tannins**

10 The retention time of compound **4** was 8.422 min, and its quasi-molecular ion peak was m/z
11 461.1089 $[M-H]^-$. After losing $C_6H_{12}O_6$ and $C_9H_8O_2$, fragments of m/z 299.0555
12 $[M-H-C_6H_{12}O_6]^-$ and m/z 331.0662 $[M-H-C_9H_8O_2]^-$ were observed. Fragment m/z 299.0555 was
13 further cleaved into fragment m/z 169.0135 after losing $C_9H_8O_2$, while fragment m/z 331.0662 was
14 further cleaved into fragment m/z 169.0135 after losing $C_6H_{12}O_6$. After cross-referencing with the
15 literature, this compound was identified as 2-*O*-cinnamoyl-glucogallin [30]. The cracking pathway
16 is shown in Fig. 9.

17 **3.4 Identification of Absorbed Bioactive Components HL**

18 **3.4.1 Alkaloids**

19 The retention time of compound **7** was 10.543 min. Its quasi-molecular ion peak was m/z
20 338.1389 M^+ , which fragmented into 323.1154 $[M-CH_3]^+$, 322.1076 $[M-CH_3-H]^+$, 308.0925
21 $[M-CH_3-CH_3]^+$, 294.1128 $[M-CH_3-H-CO]^+$, 280.0971 $[M-CH_3-CH_3-CO]^+$ daughter ions.
22 Comparison with the control samples revealed compound **7** to be jatrorrhizine. The retention time
23 of compound **8** was 10.822 min and its quasi-molecular ion peak was m/z 336.1227 M^+ , which
24 fragmented into m/z 321.1005 after losing CH_3^{\cdot} , and m/z 306.0763 after losing $2CH_3^{\cdot}$. Fragment
25 m/z 321.1005 was then further cleaved into 320.0920 $[M-CH_3-H]^+$, 292.0977
26 $[M-CH_3-H-CO]^+$ and 278.0821 $[M-2CH_3-CO]$ after losing H^{\cdot} , $H^{\cdot}+CO$, $CH_3^{\cdot}+CO$,
27 respectively. After comparison with control samples, compound **8** was identified as epiberberine.
28 The retention time of compound **9** was 10.982 min and its quasi-molecular ion peak was m/z

1 320.0912 M⁺. The parent ion was fragmented to form *m/z* 318.0763 [M-2H]⁺, and *m/z* 292.0971
2 [M-CO]⁺ ions after losing 2H⁺, and uncharged CO, respectively. Cross-referencing with the
3 control samples revealed that compound **9** was coptisine. The cracking pathway is shown in Fig.
4 [10](#). The retention time of compound **11** was 13.952 min and its quasi-molecular ion peak was *m/z*
5 352.1546 M⁺. The parent ion was cleaved into *m/z* 337.1317 [M-CH₃]⁺, 322.1076 [M-2CH₃]⁺
6 and 308.1285 [M-CHO-CH₃]⁺ ions after losing CH₃[·], 2CH₃[·], and C₂H₄O, respectively. Fragment
7 *m/z* 337.1317 was further fragmented into *m/z* 336.1239 [M-CH₃-H]⁺ after losing H,
8 respectively. Fragment *m/z* 308.1285 lost an additional CH₃[·] to form *m/z* 293.1055
9 [M-CHO-2CH₃]⁺. Cross-referencing with the control samples revealed compound **11** to be
10 palmatine. The retention time of compound **12** was 14.442 min and its quasi-molecular ion peak
11 was *m/z* 336.1228 M⁺. The parent ion was fragmented to form *m/z* 321.1006 [M-CH₃]⁺, 306.0771
12 [M-2CH₃]⁺ and 292.0976 [M-C₂H₄O]⁺ ions after losing CH₃[·], 2CH₃[·] and C₂H₄O, respectively.
13 Fragment *m/z* 321.1006 was further cleaved to form *m/z* 320.0925 [M-CH₃-H]⁺, 292.0976
14 [M-CH₃-CHO]⁺ and 278.0822 [M-2CH₃-CO] after losing H⁺, CHO and CH₃[·]+CO, respectively.
15 After cross-referencing with the control samples, compound **12** was identified as berberine [\[31\]](#).
16 The cracking pathway is shown in Fig. [11](#).

17 **3.5 Identification of Absorbed Bioactive Components from HQ**

18 **3.5.1 Flavonoids**

19 The feature fragmentation approach of flavonoids is shown in Fig. [12](#). For compound **1**,
20 under negative-ion mode, the full-scan MS detected a quasi-molecular ion of *m/z* 547.1453, with a
21 retention time of 7.182 min. Full-scan tandem MS identified the main fragment ions *m/z* 415.1032,
22 253.0505 and 225.0550 as the quasi-molecular ion without C₅H₁₀O₄, C₆H₁₀O₅ and CO,
23 respectively. After cross-referencing with the relevant literature, compound **1** was identified as
24 6-*C*-arabinosyl-8-*C*-glucosyl-chysin. Compound **2** was identified under negative ion mode, and
25 the full scan MS revealed a quasi-molecular ion at *m/z* 547.1451, with a retention time of 8.151
26 min. Full-scan tandem MS show the major fragment ions of *m/z* 385.0925 [M-H-C₆H₁₀O₅]⁻,
27 253.0501 [M-H-C₆H₁₀O₅-C₅H₈O₄]⁻ and 225.554 [M-H-C₆H₁₀O₅-C₅H₈O₄-CO]⁻. By

1 cross-referencing the literature, compound **2** was determined to be
2 6-*C*-glucosyl-8-*C*-arabinosyl-chrysin [32].

3 Compound **5** eluted at 8.591 min, and the full-scan MS under negative ion mode showed a
4 quasi-molecular ion at m/z 445.0775. Full-scan tandem MS revealed that fragment ion, m/z
5 269.0454, was 176 Da smaller than the quasi-molecular ion, due to the loss of C₆H₈O₆.
6 HPLC-MS/MS analysis was performed on a baicalin standard solution, exhibiting the same
7 retention time and fragment ions as compound **5**. Therefore, compound **5** was confirmed to be
8 baicalin. The retention time of compound **6** was 10.133 min and its quasi-molecular ion peak was
9 detected at m/z 459.0930 [M-H]⁻. The main fragment ions included m/z 283.0603
10 [M-H-C₆H₈O₆]⁻, 269.0453 [M-H-C₆H₈O₆-CH₂]⁻, 241.0495 [M-H-C₆H₈O₆-CO]⁻, and 197.0601
11 [M-H-C₆H₈O₆-CO₂-CO]⁻. The main fragment ions of this compound were identical to those of
12 compound **10**, but with different retention times. This suggests that compounds **6** and **10** were
13 isomers. Compound **10** was confirmed to be wogonoside after comparison with control samples.
14 After an additional literature search, compound **6** was identified as oroxyloside [33, 34].

15 The retention time of compound **10** was 11.161 min and its quasi-molecular ion peak was m/z
16 459.0928 [M-H]⁻. The parent ion was fragmented to form m/z 283.0609 [M-H-C₆H₈O₆]⁻ after
17 losing one molecule of glucuronic acid. Fragment ion m/z 283.0609 was further cleaved into the
18 m/z 269.0449 [M-H-CH₂]⁻ after losing CH₂. Fragment m/z 269.0449 formed the m/z 241.0498 ion
19 after losing CO at the C-4 position of the C-ring. The m/z 197.0605 ion was the fragmentation
20 product of m/z 269.0449 after losing a CO and a CO₂ molecule. After comparison with the control
21 samples, compound **10** was identified as wogonoside [33].

22 In negative ion mode, the retention time of compound **16** was 21.013 min, and its
23 quasi-molecular ion was m/z 269.0451. The tandem MS scan revealed the main fragments to be
24 m/z 251.0346, 241.0403, 223.0391 and 197.0605, which were products of the quasi-molecular ion
25 losing H₂O, CO, H₂O+CO and CO+CO₂, respectively. After comparison with the control samples,
26 compound **16** was identified as baicalein [34].

27 The retention time of compound **18** was 21.926 min and its quasi-molecular ion peak was m/z
28 283.0609 [M-H]⁻, which formed m/z 268.0375 [M-H-CH₃]⁻ after losing a methyl radical.

1 Fragment m/z 268.0375 became the m/z 240.0421 ion after losing CO at the C-4 position of the
2 C-ring, and became fragment ion m/z 224.0476 after losing CO at C-4 and O at the C-1 position of
3 the C-ring. The base peak ions m/z 239.0341 and m/z 223.0392 were fragmentation products of
4 m/z 268.0375 with the loss of COH \cdot and CO $_2$ H \cdot , and the m/z 212.0473 ion was the fragmentation
5 product upon the loss of two uncharged CO. Cross-referencing with the control samples indicated
6 that compound **18** was wogonin [33, 34]. The retention time of compound **19** was 22.093 min and
7 its quasi-molecular ion peak was m/z 283.0614 [M-H] $^-$, which fragmented into m/z 268.0375
8 [M-H-CH $_3$] $^-$, 265.0503 [M-H-H $_2$ O] $^-$ and 255.0659 [M-H-CO] $^-$ after losing CH $_3$ \cdot , H $_2$ O and CO,
9 respectively. After cross-referencing with the literature, compound **19** was preliminarily identified
10 as oroxylin A [35].

11 **4 DISCUSSION AND CONCLUSIONS**

12 In this study, chromatographs were compared among single-constituent decoction,
13 formulated decoction, serum samples and controls using the same chromatographic parameters.
14 Retention times were used to analyze and identify the chromatographic peaks upon comparison to
15 those of controls and standards. Serum samples collected at different time points were analyzed,
16 and it was found that 1 h after the intragastric administration of XXT, the rat serum samples
17 contained many constituents in the highest mass fraction. Therefore, serum samples collected after
18 60 min were selected for analysis.

19 By analyzing the transitional constituents absorbed into the blood, serum pharmacochemical
20 research can identify the material basis for the efficacy of TCM. Using the approach of serum
21 pharmacochemistry in TCM research, the transitional constituents in rat serum were analyzed after
22 oral administration of XXT using HPLC-DAD and HPLC-Q-TOF/MS. The results show that the
23 main adsorbed constituents in the serum were anthraquinones, chromones, stilbenes and tannins
24 from RRR, alkaloids from CR, flavonoids from SR. Many papers suggest that, anthraquinones
25 display the beneficial effects of antibacteria, anti-inflammation, antiviral, anticancer, etc.[36].
26 Chromones have anti-inflammatory, analgesia, antihypertensive effects, etc. [37]. Stilbenes
27 possesses a wide range of biological properties including potent anti-tumor, anti-inflammatory and
28 antioxidative effects, etc. [38, 39]. In recent years, the pharmacological action of tannins have

1 been extensively studied, mainly including bacteriostasis, hemostatic action, anticoagulant action,
2 improving renal function, etc.[40]. In recent pharmacological studies, alkaloids, main bioactive
3 components of CR have been reported to exhibit various pharmacological effects, such as
4 anti-bacterial, anti-inflammatory, anti-oxidative, anti-tumor, anti-diabetic, hypolipidemic and
5 neuroprotective activities [41-44]. Pharmacological studies have indicated that flavonoids share
6 many beneficial activities with RS with respect to anti-virus, anti-inflammatory, anti-allergic,
7 anti-oxidant and hepatoprotective properties [45-47]. Therefore, it is reasonable for
8 anthraquinones, chromones, stilbenes, tannins, alkaloids and flavonoids to be confirmed as
9 bioactive components.

10 Based on the serum pharmacochemistry of traditional Chinese medicine and HPLC/DAD
11 coupled with HPLC-Q-TOF/MS, a method for screening and analysis of the multiple absorbed
12 bioactive components and metabolites of XXT in orally dosed rat plasma has been established. As
13 a result, 21 of the constituents were separated and characterized by the methodological system,
14 which enhanced the speed and targeting of bioactive components in TCM.

15 The present study, compared with the previous studies, showed differences or improvements
16 as follows. First of all, it is that an integrated method for screening the bioactive components in rat
17 plasma after oral administration of XXT has been developed. Furthermore, according to the
18 literature, most of the identified components in dosed rat plasma possess pharmacological
19 activities; therefore, serum pharmacochemistry of traditional Chinese medicine is suitable for the
20 study of real bioactive components in XXT, and their pharmacological mechanism could be well
21 understood accordingly. In addition, the application of the method to XXT not only provided
22 chemical support for the chromatographic fingerprint technology, but also provided valuable
23 information for a comprehensive pharmacokinetics investigation of this famous formula.
24 Regrettably, due to limitations of the extraction techniques and detection tools, only a fraction of
25 the components in the formula were tentatively identified. Therefore, identification of multiple
26 absorbed bioactive components originated from the formula still needs to be done for complete
27 understanding of its mechanism.

28 **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

1 This study was approved by State Committee of Science and Technology of the People's
2 Republic of China.

3 **HUMAN AND ANIMAL RIGHTS**

4 The animal experiment was carried out according to the Regulations of Experimental Animal
5 Administration.

6 **CONSENT FOR PUBLICATION**

7 Not applicable.

8 **CONFLICT OF INTEREST**

9 The authors declare no conflict of interest, financial or otherwise.

10 **ACKNOWLEDGMENTS**

11 This work was supported by the National Natural Science Foundation of China (U1504828),
12 Science and Technology Innovation Talent Support Program of Henan College and University
13 (19HASTIT007), Basic and Cutting-edge Technologies Research Project of Henan Province
14 (152300410181), Key Research Project of Henan College and University (15B360008), Science
15 and Technology Research Projects of Nanyang (2014GG038).

16

17 **REFERENCES**

- 18 [1] Erdogan, C.S.; Vang, O. Challenges in analyzing the biological effects of resveratrol.
19 *Nutrients*, **2016**, *8* (6): 1-29.
- 20 [2] Cai, Y.; Zhang, W.; Chen, Z.; Shi, Z.; He, C.; Chen, M. Recent insights into the biological
21 activities and drug delivery systems of tanshinones. *Int. J. Nanomed.*, **2016**; *11*: 121-130.
- 22 [3] Wang, T.; Guo, R.; Zhou, G.; Zhou, X.; Kou, Z.; Sui, F.; Li, C.; Tang, L.; Wang, Z.
23 Traditional uses, botany, phytochemistry, pharmacology and toxicology of *Panax notoginseng*
24 (Burk.) F.H. Chen: A review. *J. Ethnopharmacol.*, **2016**, *188*: 234-258.
- 25 [4] Wang, X.J. Studies on serum pharmacology of traditional Chinese medicine. *Shijie*

- 1 *Kexue Jishu*, **2002**, 4: 1-5.
- 2 [5] Wang, X.J. Progress and future developing of the serum pharmacology of traditional
3 Chinese medicine. *Zhongguo Zhongyao Zazhi*, **2006**, 31: 789-792, 835.
- 4 [6] Sun, H.; Yang, L.; Li, M.X.; Fang, H.; Zhang, A.H.; Song, Q.; Liu, X.Y.; Su, J.; Yu, M.D.;
5 Makino, T.; Wang, X.J. UPLC-G2Si-HDMS untargeted metabolomics for identification of
6 metabolic targets of Yin-Chen-Hao-Tang used as a therapeutic agent of dampness-heat
7 jaundice syndrome. *J. Chromatogr. B.*, **2018**, 1081-1082: 41-50.
- 8 [7] Sun, H.; Zhang, A.H.; Yan, G.L.; Han, Y.; Sun, W.J.; Ye, Y.; Wang, X.J. Proteomics study
9 on the hepatoprotective effects of traditional Chinese medicine formulae
10 Yin-Chen-Hao-Tang by a combination of two-dimensional polyacrylamide gel
11 electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass
12 spectrometry. *J. Pharmaceut. Biomed.*, **2013**, 75: 173-179.
- 13 [8] Wang, P.; Lv, H.T.; Zhang, A.H.; Sun, H.; Yan, G.L.; Han, Y.; Wu, X.H.; Wang, X.J.
14 Improved ultra-performance liquid chromatography with electrospray ionization
15 quadrupole-time-of-flight high-definition mass spectrometry method for the rapid analysis of
16 the chemical constituents of a typical medical formula: Liuwei Dihuang Wan. *J. Sep. Sci.*,
17 **2013**, 36: 3511-3516.
- 18 [9] Zhang, Q.; Wang, C.H.; Ma, Y.M.; Zhu, E.Y.; Wang, Z.T. UPLC-ESI/MS determination of
19 17 active constituents in two categorized formulas of traditional Chinese medicine, Sanhuang
20 Xiexin Tang and Fuzi Xiexin Tang: application in comparing the differences in decoctions
21 and macerations. *Biomed. Chromatogr.*, **2013**, 27: 1079-1088.
- 22 [10] Lo, Y.C.; Tsai, P.L.; Huang, Y.B.; Shen, K.P.; Tsai, Y.H.; Wu, Y.C.; Lai, Y.H.; Chen, I.J.
23 San-Huang-Xie-Xin-Tang reduces lipopolysaccharides-induced hypotension and
24 inflammatory mediators. *J. Ethnopharmacol.*, **2005**, 96: 99-106.
- 25 [11] Ma, B.L.; Ma, Y.M.; Yan, D.M.; Zhou, H.; Shi, R.; Wang, T.M.; Yang, Y.; Wang, C.H.;
26 Zhang, N.; Normile, D. Effective constituents in Xiexin Decoction for anti-inflammation. *J.*
27 *Ethnopharmacol.*, **2009**, 125: 151-156.

- 1 [12] Lee, J.C.; Tseng, C.K.; Wu, S.F.; Chang, F.R.; Chiu, C.C.; Wu, Y.C.
2 San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced
3 cyclooxygenase-2 expression. *J. Viral. Hepatitis.*, **2011**, *18*: e315-e324.
- 4 [13] Saegusa, Y.; Sugiyama, A.; Takahara, A.; Nagasawa, Y.; Hashimoto, K. Relationship
5 between phosphodiesterase inhibition induced by several Kampo medicines and smooth
6 muscle relaxation of gastrointestinal tract tissues of rats. *J. Pharmacol. Sci.*, **2003**, *93*: 62-68.
- 7 [14] Shih, Y.T.; Wu, D.C.; Liu, C.M.; Yang, Y.C.; Chen, I.J.; Lo, Y.C. San-Huang-Xie-Xin-Tang
8 inhibits Helicobacter pylori-induced inflammation in human gastric epithelial AGS cells. *J.*
9 *Ethnopharmacol.*, **2007**, *112*: 537-544.
- 10 [15] Yan, D.; Ma, Y.; Shi, R.; Xu, D.; Zhang, N. Pharmacokinetics of anthraquinones in Xiexin
11 decoction and in different combinations of its constituent herbs. *Phytother. Res.*, **2009**; *23*:
12 317-323.
- 13 [16] Lo, Y.C.; Lin, Y.L.; Yu, K.L.; Lai, Y.H.; Wu, Y.C.; Ann, L.M.; Chen, I.J.
14 San-Huang-Xie-Xin-Tang attenuates inflammatory responses in lipopolysaccharide-exposed
15 rat lungs. *J. Ethnopharmacol.*, **2005**, *101*: 68-74.
- 16 [17] Wu, Y.N. A brief discussion on the clinical application of Yi Qing capsule. *Huaxi Yaoxue*
17 *Zazhi*, **2001**, *16*: 316-317.
- 18 [18] Jiang, M.; Li, Z.N.; Zhu, G.X. Protective role of flavonoid baicalin from Scutellaria
19 baicalensis in periodontal disease pathogenesis: A literature review. *Complement. Ther. Med.*,
20 **2018**, *38*: 11-18.
- 21 [19] Li, W.X.; Tang, Y.P.; Guo, J.M.; Shang, E.X.; Qian, Y.F.; Wang, L.Y.; Zhang, L.; Liu, P.; Su,
22 S.L.; Qian, D.W.; Duan, J.A. Comparative metabolomics analysis on hematopoietic functions
23 of herb pair Gui-Xiong by ultra-high-performance liquid chromatography coupled to
24 quadrupole time-of-flight mass spectrometry and pattern recognition approach. *J. Chromatogr.*
25 *A.*; **2014**, *1346*: 49-56.

- 1 [20] Godzien, J.; Ciborowski, M.; Angulo, S.; Ruperez, F.J.; Martínez, M.P.; Señorans, F.J.;
2 Cifuentes, A.; Ibañez, E.; Barbas, C. Metabolomic approach with LC-QTOF to study the
3 effect of a nutraceutical treatment on urine of diabetic rats. *J. Proteome. Res.*, **2010**, *10*:
4 837-844.
- 5 [21] Liu, P.; Duan, J.A.; Wang, P.J.; Qian, D.W.; Guo, J.M.; Shang, E.X.; Su, S.L.; Tang, Y.P.;
6 Tang, Z.X. Biomarkers of primary dysmenorrhea and herbal formula intervention: an
7 exploratory metabolomics study of blood plasma and urines. *Mol. Biosyst.*, **2013**, *9*: 77-87.
- 8 [22] Su, Z.H.; Li, S.Q.; Zou, G.A.; Yu, C.Y.; Sun, Y.G.; Zhang, H.W.; Gu, Y.; Zou, Z.M. Urinary
9 metabolomics study of anti-depressive effect of Chaihu-Shu-Gan-San on an experimental
10 model of depression induced by chronic variable stress in rats. *J. Pharmaceut. Biomed.*, **2011**,
11 *55*: 533-539.
- 12 [23] Ma, X.H.; Shen, S.L.; Han, F.M.; Chen, Y. The electrospray ionization-mass spectra of Radix
13 et rhizoma rhei anthraquinones. *Journal of Hubei University (Natural Science)*, **2006**, *28*:
14 403-406.
- 15 [24] Song, R.; Xu, L.; Xu, F.G.; Dong, H.J.; Tian, Y.; Zhang, Z.J. Metabolic analysis of rhubarb
16 extract by rat intestinal bacteria using liquid chromatography-tandem mass spectrometry.
17 *Biomed. Chromatogr.*, **2011**, *25*: 417-426.
- 18 [25] Jiang, H.Q.; Rong, R.; Lv, Q.T. Identification of chemical composition in Rhubarb by high
19 performance liquid chromatography with mass spectrometry. *Shizhen Guoyi Guoyao*, **2011**,
20 *22*: 1705-1706.
- 21 [26] Qu, J.L.; Xiao, N.; Sui, H.; Liang, L.; Chen, J.; Li, W.L.; Shang, D. Rapid and sensitive
22 determination of 13 components in a Traditional Chinese Medicine formula of

- 1 Da-Huang-Gan-Cao decoction by high-performance liquid chromatography coupled with
2 triple quadrupole mass spectrometry. *J. Aoac. Int.*, **2017**, *100*: 1428-1433.
- 3 [27] Li, L.Y.; Wang, Y.; Liu, M.J.; Zhang, X.; Li, X.Q.; Dai, Y.J.; Ma, Y.L.; Zhang, C. Analysis of
4 chemical components in Zhizi Jinhua Wan by UPLC-Q-TOF-MS/MS. *Zhongguo Shiyian*
5 *Fangjixue*, **2017**, *23*: 1-11.
- 6 [28] Huang, X.; Mazza, G. Simultaneous analysis of serotonin, melatonin, piceid and resveratrol
7 in fruits using liquid chromatography tandem mass spectrometry. *J. Chromatogr. A.*, **2011**,
8 *1218*: 3890-3899.
- 9 [29] Wu, B.; Liu, S.; Sun, Z.L.; Tang, Y.H.; Huang, C.G. Analysis of Plasmic and Urinary
10 Constituents after Oral Administration of Rheum palmatum, Scutellaria baicalensis and Their
11 Compatibility in Rats. *Shijie Kexue Jishu*, **2010**, *12* (4): 652-656.
- 12 [30] Liu, Y.J.; Wang, Q.; Jiang, M.; Li, H.Y.; Zou, M.J.; Bai, G. Screening of effective
13 components for inhibition of tyrosinase activity in Rhubarb based on
14 spectrum-efficiency-structure-activity relationship. *Zhongcaoyao*, **2012**, *43*: 2120-2126.
- 15 [31] Wu, W.; Song, F.R.; Yan, C.Y.; Liu, Z.Q.; Liu, S.Y. Structural analyses of protoberberine
16 alkaloids in medicine herbs by using ESI-FT-ICR-MS and HPLC-ESI-MSⁿ. *J. Pharmaceut.*
17 *Biomed.*, **2005**, *37*: 437-446.
- 18 [32] Wang, Y.Q.; Li, S.J.; Zhuang, G.; Geng, R.H.; Jiang, X. Screening free radical scavengers in
19 Xiexin Tang by HPLC-ABTS-DAD-Q-TOF/MS. *Biomed. Chromatogr.*, **2017**, *31* (11): 1-9.
- 20 [33] Ablajan, K.; Shang, X.Y.; He, J.M.; Zeper, A.; Shi, J.G. Study on flavonoids from
21 meconopsis maxim by electrospray ionization tandem mass spectrometry. *Zhipu Xuebao*,
22 **2004**, *25*: 37-38.

- 1 [34] Ablajan, K.; Zeper, A.; Shang, X.Y.; He, J.M.; Zhang, R.P.; Shi, J.G. Structural
2 characterization of flavonol 3, 7-di-O-glycosides and determination of the glycosylation
3 position by using negative ion electrospray ionization tandem mass spectrometry. *J. Mass.*
4 *Spectrom.*, **2006**, *41*: 352-360.
- 5 [35] He, Q.Y.; Song, W.F.; Ma, Y.B.; Li, R.M.; Chen, X. Identification of the major components
6 from the water extract of Radix Scutellariae by high-performance liquid chromatography
7 coupled with tandem mass spectrometry. *Zhongguo Yaowu Jingjixue*, **2012**, (5): 28-30.
- 8 [36] Xiong, Y.; Chen, L.; Fan, L.; Wang, L.; Zhou, Y.; Qin, D.; Sun, Q.; Wu, J.; Cao, S. Free Total
9 Rhubarb Anthraquinones Protect Intestinal Injury via Regulation of the Intestinal Immune
10 Response in a Rat Model of Severe Acute Pancreatitis. *Front. Pharmacol.*, **2018**, *9*: 1-13.
- 11 [37] Yu, X.X.; Wang, Z.Y.; Wang, B. Studies on the distribution and bioactivity of chromones and
12 its glycosides in plants. *Zhongguo Yaojishi*, **2010**, *13* (12): 1725-1729.
- 13 [38] Nakata, R.; Takahashi, S.; Inoue, H. Recent advances in the study on resveratrol. *Biol.*
14 *Pharm. Bull.*, **2012**, *35*: 273-279.
- 15 [39] Xin, Y.; Zhang, H.; Jia, Z.; Ding, X.; Sun, Y.; Wang, Q.; Xu, T. Resveratrol improves uric
16 acid-induced pancreatic β -cells injury and dysfunction through regulation of miR-126.
17 *Biomed. Pharmacoth.*, **2018**, *102*: 1120-1126.
- 18 [40] Ma, W.; Waffo-Téguo, P.; Alessandra Pissoni, M.; Jourdes, M.; Teissedre, P.L. New insight
19 into the unresolved HPLC broad peak of Cabernet Sauvignon grape seed polymeric tannins
20 by combining CPC and Q-ToF approaches. *Food Chem.*, **2018**, *249*: 168-175.
- 21 [41] He, K.; Hu, Y.; Ma, H.; Zou, Z.; Xiao, Y.; Yang, Y.; Feng, M.; Li, X.; Ye, X. Rhizoma
22 Coptidis alkaloids alleviate hyperlipidemia in B₆ mice by modulating gut microbiota and bile
23 acid pathways. *BBA-Mol. Basis. Dis.*, **2016**, *1862*: 1696-1709.

- 1 [42] Kaufmann, D.; Kaur Dogra, A.; Tahrani, A.; Herrmann, F.; Wink, M. Extracts from
2 traditional Chinese medicinal plants inhibit acetylcholinesterase, a known Alzheimer's
3 disease target. *Molecules*, **2016**, *21* (9): 1-16.
- 4 [43] Kim, E.; Ahn, S.; Rhee, H.I.; Lee, D.C. Coptis chinensis Franch. extract up-regulate type I
5 helper T-cell cytokine through MAPK activation in MOLT-4 T cell. *J. Ethnopharmacol.*,
6 **2016**, *189*: 126-131.
- 7 [44] Meng, F.C.; Wu, Z.F.; Yin, Z.Q.; Lin, L.G.; Wang, R.; Zhang, Q.W. Coptidis rhizoma and its
8 main bioactive components: recent advances in chemical investigation, quality evaluation
9 and pharmacological activity. *Chin. Med-UK.*, **2018**, *13*: 1-18.
- 10 [45] Zhao, K.; Li, X.; Lin, B.; Yang, D.; Zhou, Y.; Li, Z.; Guo, Q.; Lu, N. Oroxyloside inhibits
11 angiogenesis through suppressing internalization of VEGFR2/Flk-1 in endothelial cells. *J.*
12 *Cell Physiol.*, **2018**, *233* (4): 3454-64.
- 13 [46] Chen, H.; Li, Z.; Li, Y.J.; Wu, X.W.; Wang, S.R.; Chen, K.; Zheng, X.X.; Du, Q.; Tang, D.Q.
14 Simultaneous determination of baicalin, oroxylin A-7-O-glucuronide and wogonoside in rat
15 plasma by UPLC-DAD and its application in pharmacokinetics of pure baicalin, Radix
16 Scutellariae and Yinhuang granule. *Biomed. Pharmacoth.*, **2015**, *29* (12): 1819-25.
- 17 [47] Marques, M.R.; Stüker, C.; Kichik, N.; Tarragó, T.; Giralt, E.; Morel, A.F.; Dalcol, I.I.
18 Flavonoids with prolyl oligopeptidase inhibitory activity isolated from Scutellaria racemosa
19 *Pers. Fitoterapia.*, **2010**, *81* (6): 552-6.

1 **Figure Legends**

- 2 Fig. 1 The total ion chromatogram of blank serum (A), XXT (B), and serum after XXT treatment (C)
- 3 Fig. 2 The total ion chromatogram of blank serum (A), RRR (B), and serum after RRR treatment (C)
- 4 Fig. 3 The total ion chromatogram of blank serum (A), CR (B), and serum after CR treatment (C)
- 5 Fig. 4 The total ion chromatogram of blank serum (A), SR (B), and serum after SR treatment (C)
- 6 Fig. 5 Mass spectrometric fragmentation pathway of rhein
- 7 Fig. 6 Mass spectrometric fragmentation pathway of chrysophanol
- 8 Fig. 7 Mass spectrometric fragmentation pathway of resveratrol
- 9 Fig. 8 Mass spectrometric fragmentation pathway of 2-methyl-5-carboxymethyl-7-hydroxychromoglucuronide
- 10 Fig. 9 Mass spectrometric fragmentation pathway of 2-*O*-cinnamoyl-glucogallin
- 11 Fig. 10 Mass spectrometric fragmentation pathway of coptisine
- 12 Fig. 11 Mass spectrometric fragmentation pathway of berberine
- 13 Fig. 12 The feature fragmentation approach of flavonoids.